4528 — Ono Pharmaceutical Co Income Statement
0.000.00%
- ¥734bn
- ¥676bn
- ¥487bn
- 74
- 73
- 52
- 77
Annual income statement for Ono Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | IFRS | — | — | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 309,284 | 361,361 | 447,187 | 502,672 | 486,871 |
Cost of Revenue | |||||
Gross Profit | 223,711 | 267,850 | 337,125 | 375,546 | 338,921 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 210,809 | 257,921 | 305,224 | 342,737 | 427,124 |
Operating Profit | 98,475 | 103,440 | 141,963 | 159,935 | 59,747 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 100,890 | 105,025 | 143,532 | 163,734 | 59,328 |
Provision for Income Taxes | |||||
Net Income After Taxes | 75,498 | 80,685 | 112,913 | 128,040 | 50,165 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 75,426 | 80,519 | 112,723 | 127,978 | 50,046 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 75,425 | 80,519 | 112,708 | 127,964 | 49,988 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 151 | 173 | 243 | 267 | 106 |
Dividends per Share |